SCHEMBL17186375

SCHEMBL17186375

Nc1nc2[nH]cnc2c(=O)n1CCN1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5B Q9UGL1 3/20 0.39
▸ TLR7 Q9NYK1 3/20 0.39
▸ PNP P00491 1/20 0.39
▸ MPO P05164 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KDM4A O75164 2/20 0.36
▸ KDM4B O94953 2/20 0.36
▸ KDM5C P41229 2/20 0.36
▸ KDM4E B2RXH2 5/20 0.36
▸ GRIN1 Q05586 3/20 0.36
▸ GRIN2B Q13224 3/20 0.36
▸ POLB P06746 2/20 0.36
▸ TP53 P04637 2/20 0.36
▸ IP6K1 Q92551 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ CASP1 P29466 1/20 0.34
▸ KLK7 P49862 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18605582 0.99 KDM5B (0.38) KDM5BTLR7PNPMPOKMT2A
SCHEMBL17186380 0.90 GAA (0.39) TLR7KMT2AKDM4EPOLBTP53
Hydrochloric Acid SCHEMBL18605997 0.89 GAA (0.39) TLR7KMT2AKDM4EPOLBTP53
SCHEMBL17186251 0.81 HPGD (0.38) PNPHPGD
SCHEMBL3671337 0.81 PNP (0.37) PNP
SCHEMBL667794 0.81 PDE4A (0.49) HPGDHSD17B10
Hydrochloric Acid SCHEMBL17186344 0.80 HPGD (0.38) PNPHPGD
SCHEMBL9960806 0.80 PNP (0.38) KDM5BPNPKDM4AKDM4BKDM5C
SCHEMBL17186330 0.80 PIK3C2A (0.34) TLR7PNPHPGD
SCHEMBL17186419 0.79 PIK3CA (0.35) TLR7PNPHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 — — US claimed
EP-3131877-A1 GUANIDINE COMPOUNDS AND USE THEREOF Immunomet Therapeutics Inc. (US) 2017-02-22 — — EP claimed
WO-2015160220-A1 GUANIDINE COMPOUNDS AND USE THEREOF HANALL BIOPHARMA CO., LTD. (KR) 2015-10-22 — — WO claimed
EP-3131877-B1 BIGUANIDE COMPOUNDS IMMUNOMET THERAPEUTICS INC (US) 2023-07-19 — — EP disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 — — US disclosed
EP-3131877-A1 GUANIDINE COMPOUNDS AND USE THEREOF Immunomet Therapeutics Inc. (US) 2017-02-22 — — EP disclosed
WO-2015160220-A1 GUANIDINE COMPOUNDS AND USE THEREOF HANALL BIOPHARMA CO., LTD. (KR) 2015-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF PC, TFAM, PCK2 KDM5B 1084/4885TLR7 4630/4885PNP 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback